1-3 of 3
Michael Emig, MD
Close
Sort by
Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 497.
https://doi.org/10.1182/blood.V106.11.497.497
Published: 2005
Journal Articles

Early Detection of Imminent Hematologic Relapse Due to BCR-ABL Kinase Domain Mutations in CML Patients on Imatinib Therapy by D-HPLC.

Thomas Ernst, MD, Philipp Erben, MD, Thomas Schenk, MD, Martin C. Mueller, MD, Michael Emig, MD, Sebastian Kreil, MD, Paul La Rosée, MD, Ute Berger, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 1088.
https://doi.org/10.1182/blood.V106.11.1088.1088
Published: 2005
Journal Articles

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Martin C. Mueller, MD, Philipp Erben, MD, Giuseppe Saglio, MD, Enrico Gottardi, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Stephanie Lauber, MD, Michael Emig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 1991.
https://doi.org/10.1182/blood.V106.11.1991.1991
Published: 2005